{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938330,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The prognosis of patients with AML, who fail to achieve complete remission after induction therapy (=\u2009primary refractory disease) has been dismal for many years. Allo-HSCT is the only curative approach and standard of care for eligible patients in this group. The need for inducing a remission before transplantation in primary refractory patients has not been finally clarified. The objective of this retrospective single-center evaluation is to analyze the outcomes of primary refractory patients who underwent immediate allogeneic HSCT after chemotherapy induced aplasia in the context of the conditioning regimen in a real-life setting. We started a program of immediate transplantation policy for eligible patients with refractory AML after induction chemotherapy in our center in 2010. All patients with a diagnosis of primary refractory AML who underwent their first allogeneic hematopoietic stem cell transplantation in active disease between 03\/2010 and 07\/2023 at the department of Hematology at Klinikum Nuremberg, Germany, were included and analyzed. 50 patients were included in this analysis. Mean time from start of induction treatment to transplantation was 3 months (range 1.4\u20137.8 months). Melphalan (100\u2013140 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) for induction of aplasia was used in 45\/50 pts (90%) prior to conditioning. After a median follow-up of 9.97 (range: 0.03\u2013143.8) months 18\/50 (36%) patients were alive without relapse. Median and mean relapse free survival were 9.97 (range: 0.03\u2013143.8) and 28.13 (range: 0.03\u2013143.8) months respectively. The median and mean OS were 9.97 (range: 0.03\u2013143.8) and 28.64 (range: 0.03\u2013143.8) months. The 100-day, 1-year and 2-year survival rates were 66%, 48% and 42% respectively. Cumulative incidence of relapse at 2-years after transplantation was 18.5% (95% C.I., 10.3% \u2212\u200933.1%) with a median time from HSCT to relapse of 4.85 (Range: 0.67-18,3) months. Cumulative incidence of non-relapse mortality at 100 days, 1- year and 2-years was 26% (95% C.I., 16.3% \u2212\u200941.5%), 36.3% (C.I., 25.1% \u2212\u200952.5%) and 38.4% (95% C.I., 26.9% \u2212\u200954.7%) respectively. Main cause of overall mortality was TRM (58.1%) with Sepsis (41.9%) being the biggest single contributor. The only significant independent factor associated with decreased overall and 100-day survival was a positive patient CMV-status (independent of donor CMV-serostatus). The observed survival-rates in our study compare favorably to those published for established salvage-therapy regimens as well as other retrospective studies analyzing HSCT in active disease. We demonstrate that allogeneic hematopoietic stem cell transplantation in active disease is a reasonable approach for patients with primary refractory AML offering the chance for long-term survival for about one third of patients. The effect is compromised by the high incidence of non-relapse mortality.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06728-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:07:11Z","timestamp":1763129231000},"page":"6351-6358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early allogeneic stem cell transplantation after melphalan-induced aplasia leads to long-term survival in patients with primary refractory AML"],"prefix":"10.1007","volume":"104","author":[{"given":"Claudius","family":"S\u00f6hn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Wendelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"6728_CR1","doi-asserted-by":"publisher","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM (2024) Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019, (in eng), EClinicalMedicine\u00a071:102549.\u00a0https:\/\/doi.org\/10.1016\/j.eclinm.2024.102549","DOI":"10.1016\/j.eclinm.2024.102549"},{"issue":"4","key":"6728_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"2","key":"6728_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/leu.2015.226","volume":"30","author":"JM Middeke","year":"2016","unstructured":"Middeke JM et al (2016) Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia 30(2):261\u20137. https:\/\/doi.org\/10.1038\/leu.2015.226","journal-title":"Leukemia"},{"issue":"5","key":"6728_CR4","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","volume":"11","author":"M Stelljes","year":"2024","unstructured":"Stelljes M et al (2024) Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol 11(5):e324\u2013e335. https:\/\/doi.org\/10.1016\/S2352-3026(24)00065-6","journal-title":"Lancet Haematol"},{"issue":"12","key":"6728_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6728_CR6","doi-asserted-by":"publisher","unstructured":"Kanate AS, Nagler A, Savani B (2020) Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation, (in eng), Clin Hematol Int\u00a02(1): 2\u20134. https:\/\/doi.org\/10.2991\/chi.d.191207.001","DOI":"10.2991\/chi.d.191207.001"},{"key":"6728_CR7","doi-asserted-by":"publisher","unstructured":"Iacobelli S, Committee ES (2013) Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation, (in eng), Bone Marrow Transplant\u00a048 (Suppl1):S1-37.https:\/\/doi.org\/10.1038\/bmt.2012.282","DOI":"10.1038\/bmt.2012.282"},{"issue":"6","key":"6728_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjh.15137","volume":"180","author":"NK Steckel","year":"2018","unstructured":"Steckel NK et al (2018) High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 180(6):840\u2013853. https:\/\/doi.org\/10.1111\/bjh.15137","journal-title":"Br J Haematol"},{"issue":"11","key":"6728_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2020","unstructured":"Rodr\u00edguez-Arbol\u00ed E et al (2020) FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed\/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant 26(11):2165\u20132173. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"6728_CR10","doi-asserted-by":"publisher","first-page":"70.e1","DOI":"10.1016\/j.bbmt.2020.09.025","volume":"27","author":"T Tachibana","year":"2021","unstructured":"Tachibana T et al (2021) Clinical benefits of preconditioning intervention in patients with relapsed or refractory acute myelogenous leukemia who underwent allogeneic hematopoietic cell transplantation: a Kanto study of group for cell therapy multicenter analysis. Transplant Cell Ther 27(1):70.e1-70.e8. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"6728_CR11","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/leu.2017.23","volume":"31","author":"M Wattad","year":"2017","unstructured":"Wattad M et al (2017) Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia 31(6):1306\u20131313. https:\/\/doi.org\/10.1038\/leu.2017.23","journal-title":"Leukemia"},{"issue":"3","key":"6728_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","volume":"35","author":"SL Price","year":"2011","unstructured":"Price SL et al (2011) Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 35(3):301\u20134. https:\/\/doi.org\/10.1016\/j.leukres.2010.09.002","journal-title":"Leuk Res"},{"issue":"9","key":"6728_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","volume":"16","author":"F Ravandi","year":"2015","unstructured":"Ravandi F et al (2015) Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol 16(9):1025\u20131036. https:\/\/doi.org\/10.1016\/S1470-2045(15)00201-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"6728_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","volume":"122","author":"J Kr\u00f6nke","year":"2013","unstructured":"Kr\u00f6nke J et al (2013) Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 122(1):100\u20138. https:\/\/doi.org\/10.1182\/blood-2013-01-479188","journal-title":"Blood"},{"key":"6728_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/CMAR.S339846","volume":"14","author":"K Sockel","year":"2022","unstructured":"Sockel K et al (2022) Allogeneic stem cell transplantation with sequential melphalan-based conditioning in AML: residual morphological blast count determines the risk of relapse. Cancer Manag Res 14:547\u2013559. https:\/\/doi.org\/10.2147\/CMAR.S339846","journal-title":"Cancer Manag Res"},{"key":"6728_CR16","doi-asserted-by":"publisher","unstructured":"Nagler A et al Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for Relapsed\/Refractory acute myeloid leukemia: an ALWP\/EBMT analysis, (in eng). Clin Cancer Res 28(19):4258\u20134266\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0809","DOI":"10.1158\/1078-0432.CCR-22-0809"},{"issue":"5","key":"6728_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/leu.2011.13","volume":"25","author":"C Craddock","year":"2011","unstructured":"Craddock C et al (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 25(5):808\u201313. https:\/\/doi.org\/10.1038\/leu.2011.13","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06728-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:19Z","timestamp":1767485719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6728"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06728-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent to analysis of their medical data at inclusion to the AML-registry of the Study alliance leukemia (SAL). This study was conducted in compliance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}